Schwetz B.New Treatment for Chronic Myelogenous Leukemia.The Journal of The American Medical Association. 2001Schwetz BA. New Treatment for Chronic Myelogenous Leukemia. JAMA. 2001; 286:35.Schwetz BA.New treatment for chronic myelogenous leukemia[J].2001,28....
Leukemias are cancers of the blood cells. Chronic myelogenous leukemia (CML) is an uncommon type of cancer of the bone marrow, which produces blood cells. "Myelogenous" refers to the type of blood cells this leukemia affects. "Chronic" means this cancer
The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects. Leukemia and Lymphoma 1992: 6: 305-3 15.MORRA, E., LAZZARINO, M., ALIMENA, G, LIBERATI, A.M., GRIGNANI, F., MANDELLI, F., and BERNASCONI, C. (1992). The role of interferon in the ...
Interferon-alpha therapy for chronic myelogenous leukemia. Am J Med 1995; 99: 402–411. 23 Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O et al., The German CML-Study Group. Randomized comparison of interferon a and hydroxyurea with hydroxyurea monotherapy in ...
Chronic myelogenous leukemia (CML) involves the clonal expansion of hemopoietic progenitor cells associated with a characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity. Although the precise molecular event...
BACKGROUND: The treatment options for bcr-abl positive chronic myelogenous leukemia (CML) include chemotherapy, immune therapy, allogeneic stem cell transplantation, and molecular therapy. The tyrosine kinase inhibitor imatinib was approved for the treatment of CML in 2002. Data from clinical trials all...
Chronic myelogenous leukemia (CML) is a rare disease in children for which pediatric evidence-based guidelines are lacking. We designed an anonymous survey for practicing pediatric oncologists and bone marrow transplantation (BMT) physicians to assess their willingness to recommend BMT for a patient wi...
(2001) Perspectives on the future of chronic myeloid leukemia treatment. Seminars in ... JM Goldman,R Szydlo,MM Horowitz,... - 《Blood》 被引量: 622发表: 1993年 New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia BACKGROUND AND OBJECTIVE: ...
(FDA) in 2001 for the treatment of chronic myelogenous leukemia (CML), a rare form ofcancerthat affects certain types of white blood cells. Since its initial approval, Gleevec has also been approved for use in patients with several types of gastrointestinal tumors. Currently, scientists continue...
Semisynthetic homoharringtonine (ssHHT) is now being evaluated in phase II clinical trials for the treatment of chronic myelogenous leukemia and acute myel... Tang,R. - 《Molecular Cancer Therapeutics》 被引量: 257发表: 2006年 Simultaneous homoharringtonine and interferon-α in the treatment of ...